BlackDiamond Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
BlackDiamond Wealth Management's XBI Position: Q1 2026 in Review
BlackDiamond Wealth Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.7% in Q1 2026, selling an estimated $3.75K and leaving 1,740 shares worth $222K. The position accounts for 0.11% of the portfolio, ranked #183.
BlackDiamond Wealth Management first reported a position in XBI in Q2 2023 and has held it in 9 quarters since. The position peaked at $249K in Q1 2024. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- BlackDiamond Wealth Management held 1,740 shares of State Street SPDR S&P Biotech ETF worth $222K as of Q1 2026.
- BlackDiamond Wealth Management sold 30 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $3.75K.
- State Street SPDR S&P Biotech ETF made up 0.11% of BlackDiamond Wealth Management's portfolio in Q1 2026, its #183 holding.
- BlackDiamond Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2023 and has held it in 9 quarters since.
- BlackDiamond Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $249K in Q1 2024.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on BlackDiamond Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.